Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

NCT02977494 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Universitätsklinikum Hamburg-Eppendorf